Healthy Volunteers 1IPS39

You may qualify and be compensated up to $6,000 if you meet the following requirements:

• Females and males from 18 to 55 years
• Minimum weight of 50 kg (110 lbs.)
• BMI (Body Mass Index) between 18 and 30 kg/m2
• Non-smokers

Study design: The study will last up to 7 weeks (from screening to the end of the study visit), with:

• 1 screening visit,
• 1 in-patient stay of 14 nights and 15 days, 3 doses separated by 5 days without treatment between each dosing,
• 1 follow-up visit on day 18.

Access the Pre-Screening Questionnaire here.

Next check-in dates: click here for the study calendars.

Study objective:  The study aims to assess if three different commercial dosage strengths of Palovarotene (2.5 mg, 5 mg, and 10 mg capsules) act similarly in the body of healthy participants.

About the study drug: Palovarotene is a medication already commercialized by IPSEN, a global biopharmaceutical company. It is used for the treatment of fibrodysplasia ossificans progressiva, a rare, severely disabling condition that causes abnormal bone formation in place of soft and connective tissue, such as ligaments, tendons, and skeletal muscles.

For more information, contact our recruiters at 844-246-8459 or email us at recruitment@biotrial.us